Biotech Values

[poorgradstudent]

BMY / IDO:

Absent some misconduct in the INCY / MRK trial, I don't see any reason why BMY should have any hope in its similar plan.

There's some attempt for salvation on twitter by mentioning the BMY compound displaces the heme in IDO. I don't think that matters one bit. Obvious caveat is that no one has seen BMY's melanoma data for this compound. BMY had a close look at INCY's IDO through their collaborative program, and still moved ahead with their IDO.

One aspect that confused me prior to this phase 3 data release was the aggressive moves by multiple players to enter the IDO space, their willingness to start phase 3s on limited data, and the selective disclosure of P1/2 data in some indications while not disclosing others. I figured the possibilities were either that they see something, or that they're all moving forward as a competitive / don't-get-left-behind play. In hindsight it seems option 2 is the more likely answer.